poisar

Stocks · News reference

Nordson EFD to Preview New Dispensing Technologies at COMPAMED 2026

Fiscal.ai

Nordson EFD announced it will showcase two new dispensing technologies, the Ultimus AccuFlow and PICO Pµlse XP HV, at the upcoming COMPAMED 2026 trade show.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — NORDSON CORP (NDSN)

    Filed: 2026-10-23 AccNo: 0000072331-26-000063 Size: 151 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

  2. Zacks Investment ResearchZacks.Com

    Nordson (NDSN) Down 6.9% Since Last Earnings Report: Can It Rebound?

    Nordson reported strong Q3 fiscal 2026 earnings with adjusted EPS of $3.25 (beating estimates by 5.2%) and revenues of $817.67 million (up 10.3%), driven by broad organic growth across all three segments and record sales. Despite the solid results, the stock has declined 6.9% since the earnings report. The company raised full-year guidance and maintains a Zacks Rank #2 (Buy) rating with upward estimate revisions, suggesting potential for recovery.

  3. Globenewswire IncResearchandmarkets.Com

    Syringe Filling Machine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031), Syringe Filling Machine Market to Reach USD 2.99 Billion

    The global syringe filling machine market is projected to grow from USD 2.09 billion in 2026 to USD 2.99 billion by 2031 at a 7.41% CAGR. Growth is driven by rising demand for prefilled syringes, automated fill-finish lines for biologics, and regulatory focus on aseptic accuracy. Automated systems dominate with 63.92% market share, while servo-driven piston technology leads at 44.05%. Asia-Pacific emerges as the fastest-growing region at 10.72% CAGR, driven by biologics capacity expansion.